Through consultation with physicians and patients, the Canadian Breast Cancer Network (CBCN) outlined five key recommendations for consideration when implementing biosimilars in oncology

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA–(Marketwired – Aug 6, 2015) – GSK (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announce the approval in Canada of BREO® ELLIPTA® (fluticasone furoate/vilanterol […]

Latest Approval Expands Product Label in Canada and Further Strengthens Global Brand for Once-Daily, Dual Mechanism Antibiotic DUBLIN, IRELAND–(Marketwired – Jul 23, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance […]

TORONTO, ON–(Marketwired – July 20, 2015) – New research published by the Canadian Health Policy Institute (CHPI) suggests fears that the Trans-Pacific Partnership (TPP) will drive up health costs are […]